Literature DB >> 28942362

Calcitriol Treatment Ameliorates Inflammation and Blistering in Mouse Models of Epidermolysis Bullosa Acquisita.

Stefan Tukaj1, Katja Bieber2, Mareike Witte3, Saeedeh Ghorbanalipoor2, Enno Schmidt4, Detlef Zillikens4, Ralf J Ludwig4, Michael Kasperkiewicz3.   

Abstract

A link between hypovitaminosis D and development of autoimmune bullous disorders has been suggested recently, but this association has not been elaborated experimentally. Here, the role of vitamin D was investigated in epidermolysis bullosa acquisita (EBA), an anti-type VII collagen autoantibody-induced blistering skin disease. Oral administration of the hormonally active vitamin D metabolite calcitriol ameliorated clinical disease severity and dermal neutrophil infiltration in both an antibody transfer- and immunization-induced EBA mouse model. Mechanistically, calcitriol hindered immune effector cell activation as evidenced by increased L-selectin expression on Gr-1+ cells in calcitriol-treated mice with antibody transfer-induced EBA, as well as suppressed in vitro immune complex-induced reactive oxygen species production in calcitriol-treated murine neutrophils. Additionally, calcitriol administration was associated with an increase of regulatory T (CD4+FoxP3+) and B (CD19+IL10+) cells as well as reduction of pro-inflammatory T helper 17 (CD4+IL-17+) cells in mice with immunization-induced EBA. In line, levels of circulating anti-type VII collagen autoantibodies were lower in mice that received calcitriol compared to solvent-treated animals. Together with the observed state of hypovitaminosis D in most cases of an analyzed EBA patient cohort, the results of this study support the use of vitamin D derivatives or analogs for patients with EBA and related diseases.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28942362     DOI: 10.1016/j.jid.2017.09.009

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance.

Authors:  Stefan Tukaj; Katja Bieber; Wiebke Prüßmann; Jasper N Prüßmann; Enno Schmidt; Detlef Zillikens; Ralf J Ludwig; Michael Kasperkiewicz
Journal:  Arch Dermatol Res       Date:  2022-08-12       Impact factor: 3.033

Review 2.  Nutritional Interventions for Treating Cancer-Related Fatigue: A Qualitative Review.

Authors:  Julia E Inglis; Po-Ju Lin; Sarah L Kerns; Ian R Kleckner; Amber S Kleckner; Daniel A Castillo; Karen M Mustian; Luke J Peppone
Journal:  Nutr Cancer       Date:  2019-01-26       Impact factor: 2.900

Review 3.  Skin Barrier and Autoimmunity-Mechanisms and Novel Therapeutic Approaches for Autoimmune Blistering Diseases of the Skin.

Authors:  Natalie E Stevens; Allison J Cowin; Zlatko Kopecki
Journal:  Front Immunol       Date:  2019-05-14       Impact factor: 7.561

Review 4.  New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update.

Authors:  Giovanni Genovese; Giovanni Di Zenzo; Emanuele Cozzani; Emilio Berti; Massimo Cugno; Angelo Valerio Marzano
Journal:  Front Immunol       Date:  2019-07-02       Impact factor: 7.561

Review 5.  Targeting DCs for Tolerance Induction: Don't Lose Sight of the Neutrophils.

Authors:  Florianne M J Hafkamp; Tom Groot Kormelink; Esther C de Jong
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

6.  Pathological Relevance of Anti-Hsp70 IgG Autoantibodies in Epidermolysis Bullosa Acquisita.

Authors:  Stefan Tukaj; Jagoda Mantej; Krzysztof Sitko; Detlef Zillikens; Ralf J Ludwig; Katja Bieber; Michael Kasperkiewicz
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

Review 7.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.